TRACTISS RNA-seq Data

To date, the TRial for Anti-B-Cell Therapy In patients with pSS (TRACTISS) is the largest multi-centre, placebo-controlled, phase-III trial with the administration of 2 cycles of RTX (or placebo) at baseline and 24 weeks, with the trial primary and secondary endpoints evaluated at 48 weeks.

This website acts as supplementary material for:
Pontarini E et al. Serum and Tissue Biomarkers Associated With Composite of Relevant Endpoints for Sjögren Syndrome (CRESS) and Sjögren Tool for Assessing Response (STAR) to B Cell-Targeted Therapy in the Trial of Anti-B Cell Therapy in Patients With Primary Sjögren Syndrome (TRACTISS). Arthritis Rheumatol. 2024 May;76(5):763-776. doi: 10.1002/art.42772. [7].

It allows users to explore curated salivary gland RNA-seq data from the TRACTISS trial. Salivary gland biopsies were taken at baseline (Visit 4), week 16 (Visit 7), and week 48 (Visit 12) with accompanying clinical data.

TRACTISS Publications

1. Brown S, Navarro Coy N, Pitzalis C, et al. The TRACTISS Protocol: a randomised double blind placebo controlled clinical TRial of Anti-B-Cell Therapy In patients with primary Sjögren’s Syndrome. BMC Musculoskelet Disord 2014;15:21. doi:10.1186/1471-2474-15-21
2. Bowman SJ, Everett CC, O’Dwyer JL, et al. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren’s Syndrome. Arthritis Rheumatol 2017;69:1440–50. doi:10.1002/art.40093
3. Fisher BA, Everett CC, Rout J, et al. Effect of rituximab on a salivary gland ultrasound score in primary Sjögren’s syndrome: results of the TRACTISS randomised double-blind multicentre substudy. Ann Rheum Dis 2018;77:412–6. doi:10.1136/annrheumdis-2017-212268
4. Pontarini E, Sciacca E, Grigoriadou S, et al. NKp30 Receptor Upregulation in Salivary Glands of Sjögren’s Syndrome Characterizes Ectopic Lymphoid Structures and Is Restricted by Rituximab Treatment. Front Immunol 2021;12. doi:10.3389/fimmu.2021.706737
5. Arends S, de Wolff L, van Nimwegen JF, et al. Composite of Relevant Endpoints for Sjögren’s Syndrome (CRESS): development and validation of a novel outcome measure. Lancet Rheumatol 2021;3:e553– 62. doi:10.1016/S2665-9913(21)00122-3
6. Seror R, Baron G, Camus M, et al. Development and preliminary validation of the Sjögren’s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren’s syndrome. Ann Rheum Dis 2022;0:annrheumdis-2021-222054. doi:10.1136/annrheumdis-2021-222054
7. Pontarini E et al. Serum and Tissue Biomarkers Associated With Composite of Relevant Endpoints for Sjögren Syndrome (CRESS) and Sjögren Tool for Assessing Response (STAR) to B Cell-Targeted Therapy in the Trial of Anti-B Cell Therapy in Patients With Primary Sjögren Syndrome (TRACTISS). Arthritis Rheumatol. 2024 May;76(5):763-776. doi: 10.1002/art.42772.

Associated Software

• Myles Lewis, Katriona Goldmann and Elisabetta Sciacca (2021). glmmSeq: General Linear Mixed Models for Gene-Level Differential Expression.

Credits

Website development and implementation by Elisabetta Sciacca, Giulia Cavallaro, Katriona Goldmann, Myles Lewis.
Data curation carried out by Elena Pontarini.